story of the week
Association Between 5α-Reductase Inhibitor Use for Dermatologic Conditions and the Risk of Breast or Gynecologic Cancers
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of the American Academy of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
5α-reductase inhibitor exposure for dermatologic conditions does not increase the risk of female breast or gynecologic cancers: A population-based propensity score-matched cohort study
J Am Acad Dermatol 2024 Oct 20;[EPub Ahead of Print], LC Chen, TYJ Hsieh, MM SennaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.